BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24918820)

  • 1. Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.
    Kriege M; Hollestelle A; Jager A; Huijts PE; Berns EM; Sieuwerts AM; Meijer-van Gelder ME; Collée JM; Devilee P; Hooning MJ; Martens JW; Seynaeve C
    Br J Cancer; 2014 Aug; 111(5):1004-13. PubMed ID: 24918820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers.
    Kriege M; Jager A; Hollestelle A; Berns EM; Blom J; Meijer-van Gelder ME; Sieuwerts AM; van den Ouweland A; Collée JM; Kroep JR; Martens JW; Hooning MJ; Seynaeve C
    J Cancer Res Clin Oncol; 2015 Oct; 141(10):1879-87. PubMed ID: 25958056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
    Näslund-Koch C; Nordestgaard BG; Bojesen SE
    J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.
    Morra A; Schreurs MAC; Andrulis IL; Anton-Culver H; Augustinsson A; Beckmann MW; Behrens S; Bojesen SE; Bolla MK; Brauch H; Broeks A; Buys SS; Camp NJ; Castelao JE; Cessna MH; Chang-Claude J; Chung WK; ; Colonna SV; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Dennis J; Devilee P; Dörk T; Dunning AM; Dwek M; Easton DF; Eccles DM; Eriksson M; Evans DG; Fasching PA; Fehm TN; Figueroa JD; Flyger H; Gabrielson M; Gago-Dominguez M; García-Closas M; García-Sáenz JA; Genkinger J; Grassmann F; Gündert M; Hahnen E; Haiman CA; Hamann U; Harrington PA; Hartikainen JM; Hoppe R; Hopper JL; Houlston RS; Howell A; ; ; Jakubowska A; Janni W; Jernström H; John EM; Johnson N; Jones ME; Kristensen VN; Kurian AW; Lambrechts D; Le Marchand L; Lindblom A; Lubiński J; Lux MP; Mannermaa A; Mavroudis D; Mulligan AM; Muranen TA; Nevanlinna H; Nevelsteen I; Neven P; Newman WG; Obi N; Offit K; Olshan AF; Park-Simon TW; Patel AV; Peterlongo P; Phillips KA; Plaseska-Karanfilska D; Polley EC; Presneau N; Pylkäs K; Rack B; Radice P; Rashid MU; Rhenius V; Robson M; Romero A; Saloustros E; Sawyer EJ; Schmutzler RK; Schuetze S; Scott C; Shah M; Smichkoska S; Southey MC; Tapper WJ; Teras LR; Tollenaar RAEM; Tomczyk K; Tomlinson I; Troester MA; Vachon CM; van Veen EM; Wang Q; Wendt C; Wildiers H; Winqvist R; Ziogas A; Hall P; Pharoah PDP; Adank MA; Hollestelle A; Schmidt MK; Hooning MJ
    Cancer Med; 2023 Aug; 12(15):16142-16162. PubMed ID: 37401034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer].
    Adank MA; Hes FJ; van Zelst-Stams WA; van den Tol MP; Seynaeve C; Oosterwijk JC
    Ned Tijdschr Geneeskd; 2015; 159():A8910. PubMed ID: 26332814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
    Schmidt MK; Tollenaar RA; de Kemp SR; Broeks A; Cornelisse CJ; Smit VT; Peterse JL; van Leeuwen FE; Van't Veer LJ
    J Clin Oncol; 2007 Jan; 25(1):64-9. PubMed ID: 17132695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
    Schmidt MK; Hogervorst F; van Hien R; Cornelissen S; Broeks A; Adank MA; Meijers H; Waisfisz Q; Hollestelle A; Schutte M; van den Ouweland A; Hooning M; Andrulis IL; Anton-Culver H; Antonenkova NN; Antoniou AC; Arndt V; Bermisheva M; Bogdanova NV; Bolla MK; Brauch H; Brenner H; Brüning T; Burwinkel B; Chang-Claude J; Chenevix-Trench G; Couch FJ; Cox A; Cross SS; Czene K; Dunning AM; Fasching PA; Figueroa J; Fletcher O; Flyger H; Galle E; García-Closas M; Giles GG; Haeberle L; Hall P; Hillemanns P; Hopper JL; Jakubowska A; John EM; Jones M; Khusnutdinova E; Knight JA; Kosma VM; Kristensen V; Lee A; Lindblom A; Lubinski J; Mannermaa A; Margolin S; Meindl A; Milne RL; Muranen TA; Newcomb PA; Offit K; Park-Simon TW; Peto J; Pharoah PD; Robson M; Rudolph A; Sawyer EJ; Schmutzler RK; Seynaeve C; Soens J; Southey MC; Spurdle AB; Surowy H; Swerdlow A; Tollenaar RA; Tomlinson I; Trentham-Dietz A; Vachon C; Wang Q; Whittemore AS; Ziogas A; van der Kolk L; Nevanlinna H; Dörk T; Bojesen S; Easton DF
    J Clin Oncol; 2016 Aug; 34(23):2750-60. PubMed ID: 27269948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.
    Muranen TA; Blomqvist C; Dörk T; Jakubowska A; Heikkilä P; Fagerholm R; Greco D; Aittomäki K; Bojesen SE; Shah M; Dunning AM; Rhenius V; Hall P; Czene K; Brand JS; Darabi H; Chang-Claude J; Rudolph A; Nordestgaard BG; Couch FJ; Hart SN; Figueroa J; García-Closas M; Fasching PA; Beckmann MW; Li J; Liu J; Andrulis IL; Winqvist R; Pylkäs K; Mannermaa A; Kataja V; Lindblom A; Margolin S; Lubinski J; Dubrowinskaja N; Bolla MK; Dennis J; Michailidou K; Wang Q; Easton DF; Pharoah PD; Schmidt MK; Nevanlinna H
    Breast Cancer Res; 2016 Oct; 18(1):98. PubMed ID: 27716369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comparison between CHEK2*1100delC/I157T Mutation Carrier and Noncarrier Breast Cancer Patients: A Clinicopathological Analysis.
    Huszno J; Budryk M; Kołosza Z; Tęcza K; Pamuła Piłat J; Nowara E; Grzybowska E
    Oncology; 2016; 90(4):193-8. PubMed ID: 26991782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHEK2 c.1100delC allele is rarely identified in Greek breast cancer cases.
    Apostolou P; Fostira F; Papamentzelopoulou M; Michelli M; Panopoulos C; Fountzilas G; Konstantopoulou I; Voutsinas GE; Yannoukakos D
    Cancer Genet; 2015 Apr; 208(4):129-34. PubMed ID: 25835597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.
    Adank MA; Verhoef S; Oldenburg RA; Schmidt MK; Hooning MJ; Martens JW; Broeks A; Rookus M; Waisfisz Q; Witte BI; Jonker MA; Meijers-Heijboer H
    Eur J Cancer; 2013 May; 49(8):1993-9. PubMed ID: 23415889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
    Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
    J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic modifiers of CHEK2*1100delC-associated breast cancer risk.
    Muranen TA; Greco D; Blomqvist C; Aittomäki K; Khan S; Hogervorst F; Verhoef S; Pharoah PDP; Dunning AM; Shah M; Luben R; Bojesen SE; Nordestgaard BG; Schoemaker M; Swerdlow A; García-Closas M; Figueroa J; Dörk T; Bogdanova NV; Hall P; Li J; Khusnutdinova E; Bermisheva M; Kristensen V; Borresen-Dale AL; ; Peto J; Dos Santos Silva I; Couch FJ; Olson JE; Hillemans P; Park-Simon TW; Brauch H; Hamann U; Burwinkel B; Marme F; Meindl A; Schmutzler RK; Cox A; Cross SS; Sawyer EJ; Tomlinson I; Lambrechts D; Moisse M; Lindblom A; Margolin S; Hollestelle A; Martens JWM; Fasching PA; Beckmann MW; Andrulis IL; Knight JA; ; Anton-Culver H; Ziogas A; Giles GG; Milne RL; Brenner H; Arndt V; Mannermaa A; Kosma VM; Chang-Claude J; Rudolph A; Devilee P; Seynaeve C; Hopper JL; Southey MC; John EM; Whittemore AS; Bolla MK; Wang Q; Michailidou K; Dennis J; Easton DF; Schmidt MK; Nevanlinna H
    Genet Med; 2017 May; 19(5):599-603. PubMed ID: 27711073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer.
    Liu Y; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    BMC Cancer; 2015 Mar; 15():194. PubMed ID: 25884806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHEK2*1100delC homozygosity in the Netherlands--prevalence and risk of breast and lung cancer.
    Huijts PE; Hollestelle A; Balliu B; Houwing-Duistermaat JJ; Meijers CM; Blom JC; Ozturk B; Krol-Warmerdam EM; Wijnen J; Berns EM; Martens JW; Seynaeve C; Kiemeney LA; van der Heijden HF; Tollenaar RA; Devilee P; van Asperen CJ
    Eur J Hum Genet; 2014 Jan; 22(1):46-51. PubMed ID: 23652375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients.
    Wendt C; Muranen TA; Mielikäinen L; Thutkawkorapin J; Blomqvist C; Jiao X; Ehrencrona H; Tham E; Arver B; Melin B; Kuchinskaya E; Stenmark Askmalm M; Paulsson-Karlsson Y; Einbeigi Z; von Wachenfeldt Väppling A; Kalso E; Tasmuth T; Kallioniemi A; Aittomäki K; Nevanlinna H; Borg Å; Lindblom A
    Sci Rep; 2021 Jul; 11(1):14763. PubMed ID: 34285278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy.
    Meyer A; Dörk T; Sohn C; Karstens JH; Bremer M
    Radiother Oncol; 2007 Mar; 82(3):349-53. PubMed ID: 17250914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.
    Mellemkjaer L; Dahl C; Olsen JH; Bertelsen L; Guldberg P; Christensen J; Børresen-Dale AL; Stovall M; Langholz B; Bernstein L; Lynch CF; Malone KE; Haile RW; Andersson M; Thomas DC; Concannon P; Capanu M; Boice JD; ; Bernstein JL
    Br J Cancer; 2008 Feb; 98(4):728-33. PubMed ID: 18253122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel BRCA2 and CHEK2 A-C-G-C haplotype in Turkish patients affected with breast cancer.
    Haytural H; Yalcinkaya N; Akan G; Arikan S; Ozkok E; Cakmakoglu B; Yaylim I; Aydin M; Atalar F
    Asian Pac J Cancer Prev; 2013; 14(5):3229-35. PubMed ID: 23803109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications.
    Muranen TA; Greco D; Fagerholm R; Kilpivaara O; Kämpjärvi K; Aittomäki K; Blomqvist C; Heikkilä P; Borg A; Nevanlinna H
    Breast Cancer Res; 2011 Sep; 13(5):R90. PubMed ID: 21542898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.